Drug Patents owned by Biocryst
1. List of Orladeyo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10329260 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(12 years from now) | |
| US10125102 | BIOCRYST | Human plasma kallikrein inhibitors |
Apr, 2035
(12 years from now) | |
| US10662160 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(16 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10689346 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(12 years from now) | |
| US11230530 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(12 years from now) | |
| US11117867 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 3, 2027 |
| New Chemical Entity Exclusivity (NCE) | Dec 3, 2025 |
Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient
NCE-1 date: December, 2024
Market Authorisation Date: 03 December, 2020
Treatment: Prophylaxis to prevent attacks of hereditary angiodema (hae) in adults and pediatric patients 12 years of age and older; Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older
Dosage: CAPSULE;ORAL
ORLADEYO family patents
16
United States
4
Australia
4
Japan
3
Morocco
3
Lithuania
3
Israel
3
Singapore
3
China
3
EA
3
Canada
3
European Union
2
RS
2
Korea, Republic of
2
Brazil
2
Poland
2
Hungary
2
Croatia
2
Philippines
2
New Zealand
2
Denmark
1
Chile
1
Uruguay
1
Netherlands
1
Spain
1
Mexico
1
Slovenia
1
Argentina
1
Portugal
1
Colombia
1
Peru
1
Norway
1
Taiwan, Province of China
2. List of Rapivab drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6562861 | BIOCRYST | Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors |
Dec, 2023
(10 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10391075 | BIOCRYST | Antiviral treatments |
Feb, 2027
(4 years from now) | |
| US8778997 | BIOCRYST | Antiviral treatments |
May, 2027
(4 years from now) | |
Drugs and Companies using PERAMIVIR ingredient
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of acute uncomplicated influenza in patients 2 years and older; Treatment of acute uncomplicated influenza in patients 6 months and older; Treatment of acute uncomplicated influenza in adults
Dosage: SOLUTION;INTRAVENOUS
RAPIVAB family patents
12
United States
8
Korea, Republic of
4
Australia
4
Japan
3
Mexico
2
Brazil
2
EA
2
Canada
2
China
1
Hong Kong
1
South Africa
1
New Zealand
1
Malaysia
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic